Business Development
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries.
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.
Hasten Biopharma Acquires Commercial Rights in China for Roche’s Antibiotic Rocephin®
Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink). MediLink is an innovative drug development company focusing on next generation anti-body-drug conjugates (ADCs) and related technologies.
